Hunter syndrome
Drug research and approvals for hunter syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 7 studies of hunter syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 2 approved and 5 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 7
- Trials authorized in Canada: 5
- FDA orphan approvals: 2
- EU medicines: 1
- MPS (RaDiCo Cohort) (RaDiCo-MPS)NCT06036693 · Not reported · Institut National de la Santé Et de la Recherche Médicale, France · starts Dec 20, 2017
- Registry of Patients Diagnosed With Lysosomal Storage DiseasesNCT05619900 · Not reported · University of California, San Francisco · starts May 31, 2022
- PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)NCT04532047 · Phase 1 · University of California, San Francisco · starts Jul 1, 2021
- Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RICNCT04528355 · Not reported · Paul Szabolcs · starts Aug 20, 2020
- Longitudinal Study of Neurodegenerative DisordersNCT03333200 · Not reported · University of Pittsburgh · starts Jan 11, 2012
- UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like CellsNCT02254863 · Phase 1 · Joanne Kurtzberg, MD · starts Sep 1, 2014
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTNCT01962415 · Phase 2 · Paul Szabolcs · starts Feb 4, 2014
| Dec 15, 2023 | An open-label extension for subjects in studies HGT-HIT-046 and SHP609-302 evaluating long-term safety of intrathecal idursulfase-it administered in…Idursulfase-it (HGT-2310) | Takeda Pharmaceuticals USA | Ongoing |
| Oct 26, 2022 | A phase 1/2/3 multicenter, open label study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of RGX-121 in pediatric subjects with mps ii…RGX-121 / Rapamune / Prograf / Prednisolone / Medrol | REGENXBIO | Closed |
| Aug 12, 2021 | A phase 1/2, multicenter, open-label study to determine the safety, pharmacokinetics, and pharmacodynamics of DNL310 in pediatric subjects with hunter syndromeDNL310 | Denali Therapeutics | Closed |
| Apr 24, 2015 | "an open label extension of study HGT-HIT-094 evaluating long term safety and clinical outcomes of intrathecal idursulfase administered in conjunction with…HGT-2310 (idursulfast-it) | Takeda Pharmaceuticals USA | Ongoing |
| Mar 25, 2014 | A controlled, randomized, two-arm, open-label, assessor-blinded, multicenter study of intrathecal idursulfase-ot administered in conjunction with elaprase in…HGT-2310; idursulfase-it | Takeda Pharmaceuticals USA | Ongoing |
| Mar 24, 2026 | AvlayahTreatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or… | Denali Therapeutics Inc. | Approved |
| Jul 24, 2006 | ElapraseIndicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in… | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Mar 28, 2023 | Adeno-associated virus vector expressing human…Treatment of mucopolysaccharidosis (MPS) II, also called Hunter syndrome | NeuroGT, Inc. | Designated |
| Oct 15, 2018 | Humanized IgG-1 antibody targeting human transferrin…Treatment of Mucopolysaccharidosis Type II (MPS II) or Hunter Syndrome | JCR Pharmaceuticals Co., Ltd. | Designated |
| Sep 1, 2016 | Recombinant adeno-associated virus vector serotype 9…Treatment of mucopolysaccharidosis II, also called Hunter syndrome A. | University of North Carolina at Chapel Hill | Designated |
| May 15, 2013 | HIRMAb-IDSTreatment of mucopolysaccharidosis Type II (Hunter Syndrome) | ArmaGen Technologies, Inc. | Designated |
| Feb 11, 2013 | Idursulfase betaTreatment of Hunter Syndrome (mucopolysaccharidoses) | Green Cross Corp. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jan 8, 2007 | ElapraseIdursulfase | Takeda Pharmaceuticals International AG Ireland Branch | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA